|
|
|
Volumn 4, Issue 3, 2002, Pages 275-280
|
|
Technology evaluation: EPI-2010, EpiGenesis
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIASTHMATIC AGENT;
ANTISENSE OLIGODEOXYNUCLEOTIDE;
DURASON;
EPI 2010;
EPIGENRX;
UNCLASSIFIED DRUG;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ANTICOAGULATION;
ASTHMA;
BRONCHODILATING ACTIVITY;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG ABSORPTION;
DRUG EFFICACY;
DRUG ELIMINATION;
DRUG HALF LIFE;
DRUG INDICATION;
DRUG METABOLISM;
HEADACHE;
HUMAN;
IN VITRO STUDY;
IN VIVO STUDY;
NONHUMAN;
NOTE;
PHASE 2 CLINICAL TRIAL;
SIDE EFFECT;
ADMINISTRATION, INHALATION;
ANTI-ASTHMATIC AGENTS;
ASTHMA;
CLINICAL TRIALS, PHASE I;
CLINICAL TRIALS, PHASE II;
DISEASE MODELS, ANIMAL;
HUMANS;
OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE;
PHOSPHATES;
RESPIRATION DISORDERS;
STRUCTURE-ACTIVITY RELATIONSHIP;
ANIMALIA;
|
|
EID: 0036624578
PISSN: 14648431
EISSN: None
Source Type: Journal
DOI: None Document Type: Note |
|
Times cited : (7)
|
|
References (0)
|
